Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cencora, Inc.COR · Entity 2994 | Director | March 05, 2026 | March 09, 2026 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Financial Officer | May 15, 2020 | June 04, 2020 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | September 08, 2026 | September 10, 2026 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | June 13, 2019 | June 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cencora, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,081 |
Reported balance
After 2026-03-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 557 · Balance 4,081 F1: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 3/10/2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant of restricted stock units received for no consideration and vests 100% on the first anniversary of the date of grant. Receipt of shares deferred until 3/10/2029.
Moderna, Inc.
Report date May 15, 2020 · Filed June 04, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,219,910 |
Reported balance
After 2020-05-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-05-15 · Sale · Disposed 2,600 · Balance 1,219,910 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on September 18, 2019. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.27 to $64.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on September 18, 2019.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.27 to $64.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Revolution Medicines, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectTrust | 0 |
Last balance in matching sequence
After 2026-09-08 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 2 · 2026-09-08 · Sale · Disposed 706 · Balance 16,384 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F3: The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 3 · 2026-09-08 · Sale · Disposed 999 · Balance 15,385 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F5: The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 4 · 2026-09-08 · Sale · Disposed 3,587 · Balance 11,798 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F6: The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 5 · 2026-09-08 · Sale · Disposed 2,853 · Balance 8,945 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F7: The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 6 · 2026-09-08 · Sale · Disposed 4,730 · Balance 4,215 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F8: The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 7 · 2026-09-08 · Sale · Disposed 3,844 · Balance 371 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F9: The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. Row 8 · 2026-09-08 · Sale · Disposed 371 · Balance 0 F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026. F10: The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: Shares held by the Lorence Kim Revocable Trust. |
| Common StockSEC Table I · non-derivative | Direct | 1,191 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,191 F1: Includes 1,191 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,191 restricted stock units.
F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026.
F3: The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: Shares held by the Lorence Kim Revocable Trust.
F5: The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6: The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7: The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F8: The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F9: The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F10: The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Seres Therapeutics, Inc.
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2029-06-12 | Direct | 15,000 |
Reported balance
After 2019-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COWEN INC.
Report date March 01, 2023 · Filed March 01, 2023
Section 16 reporting ended · disclosed 2023-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-03-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2022 (the "Merger Agreement"), by and among The Toronto-Dominion Bank, a Canadian chartered bank ("Parent"), Crimson Holdings Acquisition Co., a Delaware corporation ("Merger Sub") and an indirect wholly owned subsidiary of Parent and Cowen Inc., a Delaware corporation (the "Company"), on March 1, 2023 (the "Effective Time"), Merger Sub merged with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the Effective Time, each share of Class A common stock, par value $0.01 per share, of the Company ("Class A Company Common Stock") issued and outstanding immediately prior to the Effective Time and each share of Class B common stock, par value $0.01 per share, of the Company (together with Class A Company Common Stock, "Company Common Stock") issued and outstanding immediately prior to the Effective Time (except for (i) shares of Company Common Stock owned by the Company or Parent (in each case, other than shares of Company Common Stock (A) held in trust accounts, managed accounts, mutual funds and the like, or otherwise held in a fiduciary or agency capacity, or (B) held, directly or indirectly, in respect of a debt previously contracted) and (ii) any shares of Company Common Stock with respect to which dissenters' rights have been exercised) was automatically canceled and converted into the right to receive $39.00 in cash, without interest (the "Merger Consideration"). |
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-03-01 · Disposition to issuer · Disposed 8,236 · Balance 0 F3: This line item represents outstanding restricted stock units held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit held by a current or former non-employee director of the Company ("Director RSU") (whether settled or unsettled) immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the number of shares of Company Common Stock subject to such Director RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F4: With respect to any Director RSUs that constitute nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and that are not permitted to be paid at the Effective Time without triggering a Tax (as defined in the Merger Agreement) or penalty under Section 409A of the Code, the payment referenced under point 3 above shall be made at the earliest time permitted under the applicable Stock Plan (as defined in the Merger Agreement) and award agreement that will not trigger a Tax or penalty under Section 409A of the Code. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2022 (the "Merger Agreement"), by and among The Toronto-Dominion Bank, a Canadian chartered bank ("Parent"), Crimson Holdings Acquisition Co., a Delaware corporation ("Merger Sub") and an indirect wholly owned subsidiary of Parent and Cowen Inc., a Delaware corporation (the "Company"), on March 1, 2023 (the "Effective Time"), Merger Sub merged with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: At the Effective Time, each share of Class A common stock, par value $0.01 per share, of the Company ("Class A Company Common Stock") issued and outstanding immediately prior to the Effective Time and each share of Class B common stock, par value $0.01 per share, of the Company (together with Class A Company Common Stock, "Company Common Stock") issued and outstanding immediately prior to the Effective Time (except for (i) shares of Company Common Stock owned by the Company or Parent (in each case, other than shares of Company Common Stock (A) held in trust accounts, managed accounts, mutual funds and the like, or otherwise held in a fiduciary or agency capacity, or (B) held, directly or indirectly, in respect of a debt previously contracted) and (ii) any shares of Company Common Stock with respect to which dissenters' rights have been exercised) was automatically canceled and converted into the right to receive $39.00 in cash, without interest (the "Merger Consideration").
F3: This line item represents outstanding restricted stock units held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit held by a current or former non-employee director of the Company ("Director RSU") (whether settled or unsettled) immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the number of shares of Company Common Stock subject to such Director RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F4: With respect to any Director RSUs that constitute nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and that are not permitted to be paid at the Effective Time without triggering a Tax (as defined in the Merger Agreement) or penalty under Section 409A of the Code, the payment referenced under point 3 above shall be made at the earliest time permitted under the applicable Stock Plan (as defined in the Merger Agreement) and award agreement that will not trigger a Tax or penalty under Section 409A of the Code.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2019 Filed Dec 10, 2019 00:27 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,306 | $20.93 | $27,334.58 |
DisclosureSEC source: 0001127602-19-034630 · form4.xml · nonDerivative · entry 5 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,510 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018, and amended on September 17, 2019. The sale was made to generate proceeds to cover the tax liability incident to the delivery of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.92 to $20.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:27 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 147,528 | $20.39 | $3,008,095.92 |
DisclosureSEC source: 0001127602-19-034630 · form4.xml · nonDerivative · entry 4 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,816 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018, and amended on September 17, 2019. The sale was made to generate proceeds to cover the tax liability incident to the delivery of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.87 to $20.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:27 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 89,698 | $19.34 | $1,734,759.32 |
DisclosureSEC source: 0001127602-19-034630 · form4.xml · nonDerivative · entry 3 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,511,344 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018, and amended on September 17, 2019. The sale was made to generate proceeds to cover the tax liability incident to the delivery of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.86 to $19.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 229,358 | $20.64 | $4,733,949.12 |
DisclosureSEC source: 0001127602-19-034630 · form4.xml · nonDerivative · entry 2 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,601,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 00:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 229,357 | $20.64 | $4,733,928.48 |
DisclosureSEC source: 0001127602-19-034630 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 01:24 UTC | Moderna, Inc. MRNA · Entity 2025 | GiftCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-029070 · form4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,142,327 F1 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. F2 · balance_after: Of the shares reported in this column, (i) 40,954 shares are subject to a restricted stock grant dated August 10, 2016, which vests as follows: 25% of the Shares to vest on the first anniversary of the vest start date of April 9, 2015, and the remainder vests in 12 quarterly installments and (ii) 273,027 shares are subject to a restricted stock grant dated August 10, 2016, which vests as follows: 25% of the Shares to vest on the first anniversary of the vest start date of November 18, 2015, and the remainder vests in 12 quarterly installments. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:19 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-19-017038 · doc4.xml · derivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 21:35 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 211,997 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-19-010857 · form4.xml · derivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,997 Underlying: Common Stock · 211,997 shares Expires 2029-03-08 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:17 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries E Preferred Stock · Derivative | 458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030855 · doc4.xml · derivative · entry 2 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018 (the "Offering"). The Series E Preferred Stock had no expiration date. F1 · price: The Series E Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018 (the "Offering"). The Series E Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series E Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018 (the "Offering"). The Series E Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series E Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018 (the "Offering"). The Series E Preferred Stock had no expiration date. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:17 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionCommon Stock | 458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030855 · doc4.xml · nonDerivative · entry 1 Kim Lorence H. · CIK 0001643746 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E Preferred Stock converted into Common Stock based on an applicable conversion ratio of 0.45859 upon the closing of the Issuer's initial public offering on December 11, 2018 (the "Offering"). The Series E Preferred Stock had no expiration date. F2 · balance_after: Of the shares reported in this column, (i) 40,954 shares are subject to a restricted stock grant dated August 10, 2016, which vests as follows: 25% of the Shares to vest on the first anniversary of the vest start date of April 9, 2015, and the remainder vests in 12 quarterly installment and (ii) 273,027 shares are subject to a restricted stock grant dated August 10, 2016, which vests as follows: 25% of the Shares to vest on the first anniversary of the vest start date of November 18, 2015, and the remainder vests in 12 quarterly installments. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 01:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000899243-18-018518 · doc4.xml · derivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: The option vests in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0000899243-17-016859 · doc4.xml · derivative · entry 1 Kim Lorence H. · CIK 0001643746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.